Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,478
datasets available to search
ShareScore release 0.9.0
Dataset results
2,478 results for “nasal”
Global gene expression of nasal epithelial cells in patients with seasonal allergic rhinitis
GEO Series GSE43523. Homo sapiens. 12 samples. Type: Expression profiling by array.
Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses
GEO Series GSE297096. Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
Gene expression analysis of nasal Ly6G+SiglecF+ double positive cells
GEO Series GSE143938. Mus musculus. 3 samples. Type: Expression profiling by high throughput sequencing.
Experimental Acute Exposure to Thirdhand Smoke and Changes in the Human Nasal Epithelial Transcriptome
GEO Series GSE129959. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
NTHi infection of Normal Human Nasal Epithelia (NHNE) for 14 days
GEO Series GSE230367. Homo sapiens; Haemophilus influenzae. 28 samples. Type: Expression profiling by high throughput sequencing.
Dual-transcriptomic analysis of human nasal transcriptome and microbiome reveals host-bacteria interactions associated with symptomatic respiratory infection [RNA-Seq]
GEO Series GSE309130. Homo sapiens. 149 samples. Type: Expression profiling by high throughput sequencing.
RNA-seq analysis identifies the effect of PM2.5 on human nasal epithelial cells cultured under air-liquid interface (ALI) conditions until differentiated.
GEO Series GSE243618. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses
GEO Series GSE275114. Homo sapiens. 70 samples. Type: Expression profiling by high throughput sequencing.
Neutrophilic inflammation and epithelial barrier disruption in nasal polyps characterize NSAID-exacerbated respiratory disease
GEO Series GSE189690. Homo sapiens. 26 samples. Type: Expression profiling by high throughput sequencing.
Dual-transcriptomic analysis of human nasal transcriptome and microbiome reveals host-bacteria interactions associated with symptomatic respiratory infection (16S validation)
GEO Series GSE309134. Homo sapiens. 53 samples. Type: Other.
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (nasal)
GEO Series GSE206149. Homo sapiens. 255 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab "
<p>This record contains raw data related to article “Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab"</p> <p>Abstract</p> <p><strong>Background and objective: </strong> Background: Dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, has been recently approved for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate to severe asthma, demonstrating a rapid onset of clinical effects. CRSwNP is characterized by an extended type-2 inflammatory involvement that can be assessed by extended nitric oxide analysis. Objective: In this study we investigated whether Dupilumab is associated with a rapid improvement in extended nitric oxide parameters, lung function and clinical outcomes in patients with CRSwNP.</p> <p><strong>Methods: </strong> : Consecutive patients with CRSwNP and indication to be treated with Dupilumab were evaluated for extended nitric oxide analysis (exhaled, FENO; bronchial, JawNO and alveolar, CalvNO components; nasal, nNO) and lung function 15 and 30 days after treatment initiation, and for clinical outcomes (nasal polyps score, NPS; quality of life questionnaires; visual analogue scales, VAS, for main symptoms, asthma control test, ACT) after 30 days of treatment initiation.</p> <p><strong>Results: </strong> 33 patients were enrolled. All extended nitric oxide and lung function parameters significantly improved after 15 days of treatment remaining stable at 30 days. NPS, VAS for main CRSwNP symptoms, quality of life questionnaires and ACT significantly improved after 30 days of treatment initiation.</p> <p><strong>Conclusion: </strong> Dupilumab is associated with very rapid improvement in type 2 inflammation in all airway districts and this is associated with improved lung function and clinical parameters in patients with CRSwNP.</p>
Dataset related to article "Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis"
<p>This record contains raw data related to article “Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis"</p> <p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition substantially impacting patients’ quality of life, typically associated with type inflammation and frequent comorbidities like asthma, and/or nonsteroidal anti-inflammatory drug exacerbated respiratory disease (N-ERD).<br> So far, there is minimal awareness and understanding of possible genetic factors associated with CRSwNP, apart<br> from patients with a clear genetic disorder such as cystic fibrosis.<br> The aims of this study were to assess the prevalence of familial link in a large cohort of patients affected by CRSwNP and to evaluate whether it was associated with specific phenotypes.</p>
Dataset related to article "Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps "
<p>This record contains raw data related to article “Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps"</p> <p>Abstract</p> <p>To date, no disease-specific tool has been available to assess the impact of chronic rhinosinusitis with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). Therefore, the purpose of this study was to develop and validate a questionnaire specifically designed to this aim: the Nasal Polyposis Quality of Life (NPQ) questionnaire. As indicated in the current guidelines, the development and validation of the NPQ occurred in two separate steps involving different groups of patients. The questionnaire was validated by assessing internal structure, consistency, and validity. Responsiveness and sensitivity to changes were also evaluated. In the development process of NPQ an initial list of 40 items was given to 60 patients with CRSwNP; the 27 most significant items were selected and converted into questions. The validation procedure involved 107 patients (mean age 52.9 ± 12.4). NPQ revealed a five-dimensional structure and high levels of internal consistency (Cronbach's alpha 0.95). Convergent validity (Spearman' coefficient r = 0.75; <em>p</em> < 0.01), discriminant validity (sensitivity to VAS score), and reliability in a sample of patients with a stable health status (Interclass Coefficient 0.882) were satisfactory. Responsiveness to clinical changes was accomplished. The minimal important difference was 7. NPQ is the first questionnaire for the assessment of HRQoL in CRSwNP. Our results demonstrate that the new tool is valid, reliable, and sensitive to individual changes.</p>
Dataset related to article "Outcomes of Non-Mucosa Sparing Endoscopic Sinus Surgery (Partial Reboot) in Refractory Chronic Rhinosinusitis with Nasal Polyposis: An Academic Hospital Experience "
<p>This record contains raw data related to article “Outcomes of Non-Mucosa Sparing Endoscopic Sinus Surgery (Partial Reboot) in Refractory Chronic Rhinosinusitis with Nasal Polyposis: An Academic Hospital Experience"</p> <p><strong>Objective: </strong> The reboot approach could be an effective treatment option to lower recurrence rates (RRs) in recalcitrant Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The purpose of this study was to investigate RR, recurrence-free survival (RFS), quality of life (QoL) improvement, and oral corticosteroid (OCS) intake in pluri-operated CRSwNP patients treated with partial reboot surgery.</p> <p><strong>Methods: </strong> A consecutive sample of patients with recalcitrant CRSwNP, ineligible for monoclonal antibodies, underwent partial reboot surgery. The 22-item SinoNasal Outcome Test (SNOT-22), Visual Analogue Scales (VAS) scores, OCS intake, and endoscopic Nasal Polyp Score (NPS) were collected pre and postoperatively. The main outcomes were RR and RFS, and comparison of disease-free time with previous endoscopic surgeries.</p> <p><strong>Results: </strong> Thirty pluri-operated patients were enrolled. Before the reboot, all had experienced disease recurrence at a mean recurrence time of 8.08 ± 2.83 months after surgery. After reboot, 7 (23.3%) had recurrence at a mean time of 16.67 ± 3.07 months (p = 0.02); none needed additional revision surgery till time of data collection. RR at 12, 18, and 24 months follow-up resulted significantly lower for reboot than other previous surgeries (p = 0.010, p = 0.002, p = 0.016, respectively); RFS difference resulted significant (log-rank test = 4.16; p = 0.04). Differences between pre-and post-operative total and single-items scores of SNOT-22 were significant (p = 0.001), as well as VAS scores (p = 0.001). Before the reboot, 21 patients (70%) took ≥2 OCS courses per year; at the latest follow-up visit, none had taken any course of OCS after reboot.</p> <p><strong>Conclusions: </strong> The reboot approach showed lower RR, longer RFS, improved QoL, and zeroing of OCS uptake. Larger samples and longer follow-up studies are needed to assess long-term efficacy and safety of this procedure.</p> <p><strong>Level of evidence: </strong> Level 4. According to the Oxford Center for Evidence-Based Medicine 2011 level of evidence guidelines, this non-randomized retrospective cohort study is classified as level 4 evidence Laryngoscope, 2022. Laryngoscope, 2022.</p> <p> </p>
An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo
ClinicalTrials.gov study NCT01076439. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal
ClinicalTrials.gov study NCT02260037. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
ClinicalTrials.gov study NCT03829579. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Measurment of GFR by Nasal Sensors
ClinicalTrials.gov study NCT01274169. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy (PBMC)
GEO Series GSE206151. Homo sapiens. 554 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.